1353 drugs not for sale (with list)

On October 20, Zhejiang Pharmaceutical Procurement Platform issued the Public Notice on the Suspension of Long-Term Non-Traded Products.
According to Cypress Blue Combs, about 1353 drugs were suspended from trading, involving commonly used drugs such as amosicillin capsules, azithromycin dispersion tablets, aspirin tablets, ampicillin capsules, onnitrid dispersion tablets, as well as chinese medicines such as octa-positive mother pills, octaparticles, cypress heart pills, plate blue root particles, bao and pills, etc.
publicity pointed out that, in accordance with the "Zhejiang Province to enhance the centralized procurement platform function to promote the health insurance drug payment standards full coverage reform program" spirit, in accordance with the unified deployment of superiors, enterprises will apply for suspension of online trading product information to be made public, publicity time: October 20, 2020 to October 26, 2020.
According to Cypress Blue, on June 29, Zhejiang Medical Insurance Bureau issued a "notice on the issuance of Zhejiang Province to enhance the centralized procurement platform function to promote the full coverage of medical insurance drug payment standards reform program", the above-mentioned notice has been officially implemented on September 1 this year.
more than 1,000 long-term non-tradable drugs were suspended, mainly in accordance with the above-mentioned notification requirements.
reform program for the drug collection platform in Zhejiang Province, unlike the drug collection system, which has been implemented for more than 10 years, has improved the drug access and exit mechanism of the platform. The
program calls for the establishment of a product withdrawal mechanism - for products that cannot be supplied for more than one year due to various reasons and are not traded for more than 1 year, have other drugs to replace, after the application of the enterprise, the provincial drug procurement center evaluation and audit, does not affect clinical drug use, to withdraw.
not accept the product being re-networked within two years of its exit.
the same time, the platform online trading products, the establishment of market-oriented exit mechanism, through the implementation of volume procurement, the implementation of small units with the same product bidding, the formulation of a common list of medical insurance payment standards and other ways to withdraw.
, drugs that exit the platform cannot be purchased online in Zhejiang province for two years.
according to the relevant provisions of the recruitment platform, public hospitals and other institutions need to purchase clinically needed drugs on the platform, drugs can not be hung on the platform, no doubt means the loss of Zhejiang Province's policy market.
addition, the platform also established the same product regulation bidding, single medical insurance payment standards and other methods to make the lack of competitive online drugs automatically exit the platform.
expect that after the same standard drugs will be compared, a single standard of medical insurance payments is limited to the same generic name of the drug reimbursement limit, which will undoubtedly put pressure on the clinical use of high-priced drugs.
medical insurance drugs, base drugs, 1 class of new drugs, etc. can be hung online according to the relevant provisions of the reform plan, 5 types of drugs can enter the platform hanging network.
First, drugs that fall within the scope of centralized procurement of medicines and have been included in the National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs (including the existing provincial supplement catalogue) under the generic dosage form and under the generic name of the National Essential Medicines Directory (2018 edition).
2 is a class 1 new drug that has been approved for market and during the monitoring period, including a class 1.1 new drug approved for market before the implementation of the new registration classification of chemicals and a class 1 drug approved for market after implementation, a class 1 therapeutic biological products, a class 1 Chinese medicine, natural drugs, which may be registered according to the "no online trading drug" pricing principle.
3. Generic drugs that are evaluated by quality and efficacy consistency, and newly approved generic drugs that are newly approved for listing on the basis of the principle of consistency with the quality and efficacy of the original drug, can be applied for registration according to the "no online trading drug" pricing principle.
Ivy is the online transaction of generic drugs through the quality and efficacy of consistency evaluation of the corresponding evaluation of the comparation of preparations or original drugs, according to the "no online trading drugs" pricing principle can be applied for the Internet.
5 is the same generic name and dosage form products as those already traded online (excluding low-cost drugs, tight supply of drugs, originally cheap drugs, general large infusions, and volume procurement of drugs with generic names).
the above-mentioned five categories of drugs on the internet, the programme also provides for the conditions for the network, specifically, mainly in terms of price requirements, in general, is not high.
, if there are special circumstances such as price and quality complaints or objections to a drug, it shall be decided whether to hang up the net or suspend the transaction by organizing expert screening, evaluation or negotiation.
Drug in the price and procurement sector is facing greater pressure in addition, Zhejiang Province's collection reform program also proposed to promote the expansion of platform services, to encourage fixed-point private medical institutions and fixed-point retail pharmacies to voluntarily enter the platform procurement, improve the platform service transaction subject function.
it is not difficult to see that with the expansion of the procurement entity of the collection platform, the suspended drug will lose a greater market share accordingly. The
plan stipulates that all medicines (excluding self-purchased products) included in the medical insurance catalogue traded online by the pharmaceutical procurement platform in Zhejiang Province shall be included in the scope of medical insurance drug payment;
The relevant person in charge of the Zhejiang Provincial Health Insurance Bureau pointed out that before, because private medical institutions and retail pharmacies were not included in the scope of centralized recruitment, to a certain extent, there are some non-winning drug prices falsely high problem, increasing the burden of insured people and health insurance funds.
the reform is to improve the bidding mechanism and complement the short board of the system by integrating the two functions of drug recruitment and medical insurance payment.
through the unified medical insurance drug payment standards, will plug the fixed-point private medical institutions and retail pharmacies some of the drug prices inflated policy loopholes.
that is, the subsequent sale of high-priced drugs by private medical institutions and hospitals will be curbed.
according to the plan, for medical insurance catalog drugs, national basic drugs, class 1 new drugs and other drugs that meet the conditions of the internet, all included in the platform online trading scope.
, the number of drugs traded online on the drug recruitment platform in Zhejiang province increased from 144,000 to 171,000, according to the Ministry of Health.
, according to the plan, in this expansion, the price of all drugs must not be higher than the national minimum price, to encourage prices have a clear advantage in the product priority access.
, in addition to the non-compliant drugs will be forced to withdraw, eligible drugs will also be eligible for the internet.
, the program also provides that the provincial drug procurement center regularly announces the situation of self-purchased products, focusing on monitoring the high unit price, large purchase amount and medical institutions to purchase more products.
Overall, measures such as establishing a dynamic adjustment mechanism for provincial-level recruitment platforms to promote the suspension of drug transactions that do not meet the relevant requirements, monitoring the prices and procurement of drugs on the Internet, and linking drug recruitment to medical insurance payment standards are being pushed away in many provinces.
long term, in the pharmaceutical network and procurement process, some products that do not have an advantage in terms of price and quality will face greater pressure to reduce prices and the risk of losing their policy market access qualification.
.